House appropriators, as expected, have added a rider to 2018 FDA funding legislation directing that the agency suspend any efforts to finalize its laboratory-developed test guidance proposed Oct. 3, 2014 – but the agency already completely stopped work on its LDT guidance activities in January. (Also see "House Appropriators Will Tell US FDA 'Don't Finalize' LDT Guidance In 2018 Funding Bill" - Medtech Insight, 29 June, 2017.)
The Appropriations Committee passed an Agriculture/FDA funding bill July 12 that would give FDA a total of $2.8bn in discretionary...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?